Imidazolium-based ionic liquid functionalized mesoporous silica nanoparticles as a promising nano-carrier: response surface strategy to investigate and optimize loading and release process for Lapatinib delivery
Creators: name: Peyvand, Parvaneh
name: Vaezi, Zahra
name: Mosslim Sedghi
name: Dalir, Nima
name: Ma'mani, Leila
name: Naderi-Manesh, Hossein
Publisher: name: Taylor & Francis
Year: 2020
Subjects: subject: Biophysics
subject: Biochemistry
subject: Space Science
subject: Pharmacology
subject: Biotechnology
subject: 39999 Chemical Sciences not elsewhere classified
subject: FOS: Chemical sciences
subject: FOS: Chemical sciences
subject: Cancer

description: Imidazolium-based ionic liquid functionalized PEGylated mesoporous silica nanoparticles MCM-41 (denoted as [ImIL-PEGylated@MCM-41] NPs) is synthesized and evaluated as an efficient and reliable pH-sensitive nano-carrier for controlled release of cationic Lapatinib (Lap) drug. This nano-DDS was fully characterized by dynamic light scattering, scanning electron microscopy, X-ray powder diffraction, Fourier transform infrared spectroscopy, N<sub>2</sub> adsorption–desorption measurement, and differential scanning calorimeter. Furthermore, the drug loading content and <i>in-vitro</i> drug release profile were studied. The entrapment and loading efficiency of the optimized formulation for Lap were 91 ± 2.0% and 32.21 ± 2.70%, respectively. The results of cytotoxicity assay demonstrated that ImIL-PEG@MCM-41 has no significant toxicity on both cancerous and normal cell lines and the anticancer activity of Lap@ImIL-PEG@MCM-41 was comparable to free drug in case of human breast cells (SKBR3) and human embryonic kidney 293 cells (HEK-293). Meanwhile, three-dimensional (3D) cell culture was performed by multicellular tumor spheroids for understanding of cell response to drugs in physiologically 3D microenvironments. The results of Lap@ImIL-PEG@MCM-41 uptake during 48 hours showed a gradual release of the Lap through the multicellular tumor spheroids. This showed that the pH-responsive controlled release of Lapatinib leads to the satisfactory results in the <i>in vitro</i> breast cancer therapy. HighlightImidazolium-based ionic liquid functionalized PEGylated mesoporous silica nanoparticles MCM-41 was preparedHigh entrapment efficiency of [ImIL-PEG@MCM-41] was evaluated in Lapatinib delivery to breast cancer cellsIt showed pH-responsive controlled and highly programmed release <i>in vitro</i> breast cancer therapyThe pure nanoparticles have no cytotoxicity against SKBR3, and HEK-293Biocompatibility, high loading and controllability make it a robust tool in biomedicine usage Imidazolium-based ionic liquid functionalized PEGylated mesoporous silica nanoparticles MCM-41 was prepared High entrapment efficiency of [ImIL-PEG@MCM-41] was evaluated in Lapatinib delivery to breast cancer cells It showed pH-responsive controlled and highly programmed release <i>in vitro</i> breast cancer therapy The pure nanoparticles have no cytotoxicity against SKBR3, and HEK-293 Biocompatibility, high loading and controllability make it a robust tool in biomedicine usage The application of the modified mesoporous silica nanoparticles by ionic liquid for increase loading of cationic Lapatinib drug